In vitro Evaluation of Helicobacter pylori Inhibition by Artemisia absinthium and Eugenia caryophyllata Extracts with Black Seeds Honey
-
Published:2019-07-23
Issue:3
Volume:9
Page:244-247
-
ISSN:2210-3155
-
Container-title:The Natural Products Journal
-
language:en
-
Short-container-title:NPJ
Affiliation:
1. Department of Analytical and Food Chemistry, Faculty of Pharmacy, Al-Andalus University for Medical Sciences, Tartous, Syrian Arab Republic
Abstract
Objective:
Helicobacter pylori is a Gram-negative, spiral-shaped, microaerophilic bacterium
that infects about half the world’s population and is responsible for a significant cause of morbidity
and mortality imposing a major burden on health care systems worldwide. The treatment for
eradication of H. pylori is complicated, requiring a combination of different antibiotics and gastric
acid inhibitors; and often cause nausea, antibiotic resistance, recurrence and other side effects. As a
result, there is a growing interest in compounds with natural origins because of their broad flexibility
and low toxicity.
Methods:
Broth microdilution and agar diffusion methods were used to investigate the in vitro efficacy
of Artemisia absinthium, Eugenia caryophyllata and black seed honey mixtures against H. pylori.
Results:
The different combinations used in this study inhibit the growth of H. pylori more effectively
than levofloxacin, amoxicillin and clarithromycin in both gastric pH and the pH level of the
prepared mixtures.
Conclusion:
These results indicate that the use of a combination containing 5 and 10% aqueous extracts
of E. caryophyllata and A. absinthium respectively with 12.5 or 25% black seed honey may
prevent H. pylori growth in vitro.
Publisher
Bentham Science Publishers Ltd.
Subject
Complementary and alternative medicine,Drug Discovery
Reference22 articles.
1. Cover T, Blaser M. ASM News,
: A bacterial cause of gastritis, peptic ulcer disease, and gastric cancer.,, 1995, 61,, 21-26, 2. Kusters JG, van Vliet AH, Kuipers EJ. Clin Microbiol Rev, Pathogenesis of infection.,, 2006, 19,, 449-490, 3. Mégraud F, Lehn N, Lind T, Bayerdorffer E, O’morain C, Spiller R, Unge P, van Zanten SV, Wrangstadh M, Burman CF. Antimicrob Agents Chemother, Antimicrobial susceptibility testing of in a large multicenter trial: The MACH 2 study.,, 1999, 43,, 2747-2752, 4. Meyer JM, Silliman NP, Wang W, Siepman NY, Sugg JE, Morris D, Zhang J, Bhattacharyya H, King EC, Hopkins RJ. Ann Intern Med, Risk factors for resistance in the United States: The surveillance of antimicrobial resistance partnership (SHARP) study, 1993-1999.,, 2002, 136,, 13-24, 5. Canducci F, Armuzzi A, Cremonini F, Cammarota G, Bartolozzi F, Pola P, Gasbarrini G, Gasbarrini A. Aliment Pharmacol Ther, A lyophilized and inactivated culture of increases eradication rates.,, 2000, 14,, 1625-1629,
|
|